Early Work Supports Apitegromab’s Safety as SMA Muscle Therapy

Early Work Supports Apitegromab’s Safety as SMA Muscle Therapy

300432

Early Work Supports Apitegromab’s Safety as SMA Muscle Therapy

A series of toxicology studies in rats and macaque monkeys confirmed the safety and tolerability of apitegromab, an investigational spinal muscular atrophy (SMA) therapy, supporting its ongoing assessment in patient trials, a study reported. The study, “Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease,” was published in the journal International Journal of Toxicology. In SMA, muscle tissue is atrophied and weakened. One potential treatment…

You must be logged in to read/download the full post.